Valbonne, France, September 13, 2017, 5.45 pm CEST
TxCell SA (FR0010127662 – TXCL), a biotechnology company developing innovative, personalized cellular immunotherapies using regulatory T cells (Treg) to treat severe inflammatory and autoimmune diseases as well as transplant rejection, today announces that new preclinical data will be presented at the 18th Congress of the European Society for Organ Transplantation (ESOT) to be held in Barcelona from Sept 24-27, 2017.
An oral presentation entitled ‘Alloantigen-specific regulatory T-cells generated with a chimeric antigen receptor’ will be made on September 26, 2017 at 11.50 am CEST by Megan Levings, PhD, Professor, Department of Surgery, University of British Columbia (UBC) and Head, Childhood Diseases Research Theme, BC Children's Hospital in Vancouver, Canada. TxCell and UBC have been collaborating on the development of a CAR-Treg-based cellular immunotherapy for the prevention of graft rejection in the context of solid organ transplantation since October 2016.
Further details will be communicated in due time. The full program is available on the conference website https://esot2017.esot.org/.